Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Matched comparison with the Canadian Myeloma Research Group National Clinical Database finds t(11;14) pts had similar PFS1 (44 (95% CI: 32-51) months vs. 44 (36-65), but shorter PFS2 (18 (95% CI: 11-22) months vs. 32 (23-49) months).”
Title: Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database
Authors: Julia Varghese, Christopher P Venner, Martha Louzada, Donna Reece, Darrell White, Smriti Sharma, Jiandong Su, Michael P Chu, Victor H Jimenez-Zepeda, Arleigh McCurdy, Kevin Song, Hira Mian, Michael Sebag, Julie Stakiw, Anthony Reiman, Rami Kotb, Muhammad Aslam, Rayan Kaedbey, Debra Bergstrom, Engin Gul, and Richard LeBlanc
You can read the Full Article in Clinical Lymphoma, Myeloma and Leukemia.

You can find more posts featuring Robert Orlowski on OncoDaily.